IDEAYA Biosciences Appoints Darrin Beaupre As Chief Medical Officer

RTTNews | 985 gün önce
IDEAYA Biosciences Appoints Darrin Beaupre As Chief Medical Officer

(RTTNews) - Oncology company IDEAYA Biosciences, Inc. (IDYA) announced that Darrin Beaupre has joined the company as its Chief Medical Officer, effective November 21, 2022.

Beaupre's extensive career includes various clinical development and translational research roles in industry, including most recently at BioSplice Therapeutics as Chief Medical Officer and Head of Research and Development in Oncology.

Beaupre previously served as Senior Vice President, Head of Early Oncology Development and Clinical Research at Pfizer, Inc., where he led cross-disciplinary groups including clinical development, clinical pharmacology, translational oncology and clinical operations related study clinicians.

Beaupre also served at Pharmacyclics (Abbvie) as Vice President, Head of Early Development and Immunotherapy, and at Amgen as Medical Director.

He was previously an Assistant Professor at the H. Lee Moffitt Cancer Center and Research Institute, and also held various earlier appointments at the University of Miami and the M.D. Anderson Cancer Center.

Etiketler: IDYA
read more
IDEAYA Biosciences Q4 Results Misses Estimates

IDEAYA Biosciences Q4 Results Misses Estimates

IDEAYA Biosciences, Inc. (IDYA), a precision medicine oncology company, announced net loss of $32.64 million or $0.52 per share, wider than $23.07 million or $0.50 per share in the prior-year quarter.
RTTNews | 536 gün önce
IDEAYA Biosciences Says FDA Clears IND For Pol Theta Helicase Development Candidate GSK101

IDEAYA Biosciences Says FDA Clears IND For Pol Theta Helicase Development Candidate GSK101

Oncology company IDEAYA Biosciences, Inc. (IDYA) announced Monday the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for initiation of a GSK-sponsored Phase 1/2 clinical trial to evaluate GSK101 (IDE705) for the treatment of patients having tumors with BRCA or other homologous recombination (HR) mutations or homologous recombination deficiency (HRD).
RTTNews | 719 gün önce
Swiss Market Ends Marginally Up

Swiss Market Ends Marginally Up

The Switzerland market ended marginally up on Friday despite exhibiting weakness for much of the time past noon. Investors continued to react to earnings and assess the economic impact of reciprocal tariffs, and stayed largely cautious with their moves. A report showing a drop in Swiss consumer confidence in the month of July hurt sentiment.
RTTNews | 17s 21 dakika önce
Major European Markets Close On Mixed Note

Major European Markets Close On Mixed Note

Major European markets turned in a mixed performance on Friday with investors largely staying cautious, assessing the impact of tariffs on global economic growth, and continuing to digest corporate earnings announcements and other data.
RTTNews | 17s 45 dakika önce
Positive Start Seen For Canadian Stocks

Positive Start Seen For Canadian Stocks

Canadian stocks may edge up a bit in early trades Friday morning with some encouraging earnings announcements and firm commodity prices aiding sentiment. Investors will also be reacting to the data showing a 41,000 jobs drop in Canadian employment in the month of July. Data from Statistics Canada also showed that the unemployment rate in Canada came in unchanged at 6.9%.
RTTNews | 22s 18 dakika önce
UK Market Roughly Flat; Mining Stocks Move Higher

UK Market Roughly Flat; Mining Stocks Move Higher

Amid a lack of economic and earnings data, U.K. stocks are moving in a tight range in somewhat lackluster trade on Friday. Investors are assessing the potential impact of the Trump administration's reciprocal tariffs on global economic growth. Optimism about a rate cut by the Fed next month is aiding sentiment a bit.
RTTNews | 1 gün önce